Trials / Completed
CompletedNCT04508660
CGB-400 for the Reduction of Facial Redness
Effectiveness of CGB-400 (Cosmetic) for the Reduction of Facial Redness
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- CAGE Bio Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Open-label multicenter study using CGB-400 Gel (cosmetic) to reduce facial redness
Detailed description
This is a Open-label multicenter study to evaluate the ability of CGB-400 Gel to reduce facial redness typically associated with rosacea. Approximately 25 subjects will be enrolled. Subjects will receive study treatment for 4 weeks and attend a total of 4 study visits (BL, W1, W2, W4).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CGB-400 | BID application |
Timeline
- Start date
- 2018-10-26
- Primary completion
- 2019-04-18
- Completion
- 2019-04-18
- First posted
- 2020-08-11
- Last updated
- 2020-08-11
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04508660. Inclusion in this directory is not an endorsement.